Specializes in developing cancer therapeutics targeting the p53 tumor suppressor protein pathway.
Aprea Therapeutics, Inc. is a pioneering biopharmaceutical firm dedicated to advancing synthetic lethality-based cancer therapeutics that specifically target crucial pathways and central targets involved in DNA damage response and cancer progression. Based in Doylestown, Pennsylvania, the company is at the forefront of developing innovative treatments that exploit synthetic lethality to selectively target cancer cells while sparing healthy tissue.
At the heart of Aprea Therapeutics' pipeline is ATRN-119, a promising clinical-stage small molecule ATR inhibitor designed for the treatment of solid tumor indications. This lead program exemplifies the company's committment to leveraging cutting-edge research and development to address significant unmet medical needs in oncology.
With a strategic focus on advancing therapies that enhance the precision and efficacy of cancer treatment, Aprea Therapeutics continues to drive forward its mission of transforming the landscape of cancer care through scientific innovation and therapeutic excellence.